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Abstract
Objective: To explain differences in survival in the first three years of combination anti-retroviral therapy (cART) between
HIV treatment centres in the Netherlands.
Methodology/Principal Findings: We developed a mathematical simulation model, parameterised using data from the
ATHENA cohort that describes patients entering care, being monitored and starting cART. Three scenarios were used to
represent three treatment centres with widely varying mortality rates on cART that were differentiated by: (i) the
distribution of CD4 counts of patients entering care; (ii) the age distribution of patients entering care; (iii) the average rate of
monitoring the patients not on cART. At the level of the treatment centre, the fraction of Dutch MSM dying in the first three
years of treatment ranged from 0% to 8%. The mathematical model captured the large variation in observed mortality
between the three treatment centres. Manipulating the age-distribution of patients or the frequency of monitoring did not
affect the model predictions. In contrast, when the same national average distribution of CD4 count at entry was used in all
the scenarios, the variation in predicted mortality between all centres was diminished.
Conclusions/Significance: Patients entering care with low CD4 counts appears to be the main source of variation in the
mortality rates between Dutch treatment centres. Recruiting HIV-infected individuals to care earlier could lead to substantial
improvements in cART outcomes. For example, if patients were to present with at least 400 CD4 cells/mm
3, as they do
already in some centres, then our model predicts that the mortality in the first three years of cART could be reduced by
approximately 20%.
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Introduction
The Dutch Ministry of Health recognises 24 general and
academic hospitals as HIV treatment centres in the Netherlands.
The treatment centres and the HIV Monitoring Foundation
(HMF) [1] are required to systematically monitor the quality of
care they provide and patient outcomes. However, comparing
different centres is not straight forward because indicators of
good patient management and successful treatment (combination
Anti-retroviral Therapy: cART) initiation are influenced by
the characteristics of the patients that present as well as by the
attributes of the centre itself.
Recent modelling studies have highlighted the theoretical
importance of frequently monitoring CD4 changes over time
and ensuring that cART programmes can recruit individuals early
in infection [2]–[3]. This is because cART outcomes are strongly
determined by the CD4 cell count when treatment is started [4–6];
if individuals do not enter care early, the possibility of initiating
treatment when its effect is greatest is lost, and if individuals are
not monitored frequently, it is less likely that treatment can be
initiated at the right time [3]. It has also been shown that cART
outcomes are linked to age, with older patients tending to have
higher mortality rates in the first years of treatment.
Here, we explore different hypotheses to explain different
observed mortality rates in Dutch treatment centres. The
hypotheses are: (1) the quality of treatment administered varies
between the treatment centres; (2) more frequent patient
monitoring in some centres generates better patient survival; or
(3) patients entering care earlier in some centres generates better
patient survival. Our approach is to compare the observed
mortality of patients in treatment centres with the predictions of a
mathematical model that is parameterised to reflect the variation
in the profile of patients entering care at each centre and the
frequency of monitoring. Other aspects of the model and HIV
disease are parameterised using data collected in the Netherlands
in a national observation cohort [7].
Results
Observed Survival Outcomes
At the individual level, there was no indication that survival
rates stratified by starting CD4 cell count varied between patients
attending the different treatment centres (p=0.42). For men
starting treatment with CD4 cell counts less than 50, 11% die in
the first three years; with CD4 cell counts 50–200, 2% die; with
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greater than 350, 0% die. Across all treatment centres, Dutch
MSM who present with CD4 cell count ,200 cell/mm
3 have a
75% higher risk of dying in the first 3 years on cART compared to
those who present with $350 cell/ mm
3 (adjusted HR: 1.75; 95%
CI: 1.01–3.01).
At the level of the treatment centre, the fraction of Dutch MSM
dying in the first three years of treatment ranged from 0% to 8%.
MSM treated in centre A had the same risk of dying as the
national average (HR: 1.08; 0.51–2.29). In centre B, no men died
in the first three years of treatment, so the risk of dying was
estimated as zero. The risk of dying whilst on treatment in centre
C was higher than the national average (HR: 2.22; 95% CI: 0.53–
9.53). The higher risk of dying in this centre was highly statistically
significant when all those treated were considered, but it does not
reach statistical significance when only MSM are included in the
analysis due the much smaller sample size (N=36).
Variation in Patients at Treatment Centres
Figure 1 shows the cumulative distribution of CD4 counts
among Dutch MSM presenting at the three treatment centres for
the first time. The patients presenting at centre C typically had
much lower CD4 counts than patients presenting at treatment
centres A and B. The age of patients entering care was similar in
all centres (mean age 32–34 years). Patients in care but not on
treatment were observed, on average, every 5–6 months in centre
A and B and every 3–4 months in centre C.
Comparison with Model
When the model is parameterised using the age distribution,
frequency of monitoring and the distribution of CD4 cell counts
at entry to care observed in each of the three treatment centres,
the model captures the large variation in observed mortality on
cART (Figure 2, cross). In particular, the model replicates the
substantially greater risk of dying for patients in centre C (Figure 2).
If the rate of monitoring is increased in the model, mortality is
slightly reduced in all centres by 5–10%. However, the model
predicts large differences in overall mortality rates between the
three treatment centres, even when the same monitoring
frequency is used. Changing the age-distribution of patients in
each treatment centre does not materially alter the overall survival
rates on treatment. This is because the age of patients is not
strongly independently linked to survival on cART, and the faster
progression of older patients does not lead to substantially fewer of
them starting treatment with the frequency of monitoring that is
assumed here.
In contrast, when the same (national average) distribution of
CD4 count at entry to care was used to simulate the three
treatment centres (but with other parameters reflecting the
differences between the centres), the model does not indicate an
excess risk of dying at centre C and the variation between all
centres is diminished (Figure 2, circles). This result is also found
when lower and higher thresholds for starting treatment are
assumed (Figure S1).
Discussion
Large differences in survival on cART were observed in
treatment centres in the Netherlands – the range of hazard rates
during the first years on treatment varied between 0.34 and 3.28
over the 24 treatment centres. Based on recent modelling work [3],
we hypothesised that this could be due to difference in standards of
administering treatment at the centres, differences in the frequency
of monitoring patients or variation in the profile of patients
entering care (age and CD4 cell count when first presenting).
When stratified by CD4 cell count at treatment initiation, survival
in the subset of centres that we studied was very similar, indicating
comparable standards of clinical management for the individual.
The small differences in the frequency of clinical monitoring
between the centres was not consistent with more frequent
monitoring leading to better survival as we predicted. In the
model, it was found that changes in the frequency of monitoring
had little influence of the predicted mortality rates. The age of
patients entering care was similar in all the treatment centres and
did not explain differences in mortality rates. However, there was
great variation in the CD4 cell count levels of patients entering
care at the difference centres. For the model to qualitatively
replicate the observed variation in mortality between the centres,
including these different CD4 cell count distribution was both
necessary and sufficient. We conclude that most of the observed
variation in mortality between treatment centres can be explained
by the timing of patients entering care.
Mathematical models have highlighted the importance of
monitoring individuals from early intheir infection [3]. In developed
and developing countries alike [6,8,9], cART is more effective when
started at higher CD4 levels, but not all patients enter care early
enough to allow this [10]. Models also suggest that monitoring
Figure 1. Distribution of CD4 count at presentation in three
hospitals. Dots show data and lines show fitted Weibull curves with
shape (a) and scale (b) parameters as follows: Hospital A a=1.43
b=414.46; Hospital B a=1.83 b=505.12; Hospital C a=1.06 b=236.45.
doi:10.1371/journal.pone.0001949.g001
Figure 2. Observed and modeled risk of dying in first three-
years of ART relative to national average. Errorbars show 95%
confidence interval (data) or inter-quartile range from 500 simulations
(model).
doi:10.1371/journal.pone.0001949.g002
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12 months)beforetheyneedtreatmentcanfacilitatetreatmentbeing
started at the right time. However, this effect was not strong for this
population and itwasoutweighed by thelargerinfluence of CD4 cell
countatentryto care.Thismaybebecausethe rangeoffrequencyof
monitoring rates in the treatment centres was very narrow (mean
interval between appointments in all centres ranged between 3 and
5 months) and the marginal benefit of monitoring more often is
less when patients are already monitored that frequently. In our
present analysis, the treatment centre with the highest frequency of
monitoring (centre C) also had the highest mortality rate, and this
may be due to clinicians scheduling more frequent appointments in
response to the more advanced conditions among their patients due
to the late entry to care.
We have used a novel approach to overcome the individual-
level confounding effects that can undermine comparisons
between health-care services. The complex, multi-faceted and
non-linear nature of the relationship between patients, treatment
centres and cART outcomes mean that statistical modelling may
fail to completely adjust for all potentially confounding factors. In
addition, statistical models can only provide phenomenological
insights, whereas our modelling approach affords a mechanistic
interpretation of the observed patterns. Our modelling work has
provided independent evidence of the main factors determining –
and limiting – survival outcomes on cART. We have also been
able to test and verify modelling predictions with high-quality
observational data.
The implication of our findings is that survival outcomes in
many Dutch treatment centres would improve if patients entered
care earlier in their HIV infection. Although most individuals are
regularly tested for HIV and enter care when still healthy, still a
substantial proportion of Dutch MSM (25%) presents after they
have developed severe symptoms of immune-suppression [11]. In
fact, Dutch MSM tend to present at the clinic with only marginally
higher CD4 counts than men and women in West Africa [12].
Most of those entering care with high CD4 counts in centre B
(the centre with the lowest mortality rates and patients entering the
care earliest) were routinely tested for HIV as part of an ongoing
cohort study. If Dutch MSM across the country were to enter care
at the same time, then our model predicts that the mortality in the
first three years of cART could be reduced by approximately 20%.
Increased and early HIV testing is required for the full impact of
cART to be realised in the Netherlands, because even the highest
standards of clinical management cannot make up for the lost
benefit of treating patients early.
Methods
Data: Treatment Outcomes and Profile of Patients in
Dutch Treatment Centres
The risk of dying in the first three years on cART for all patients
was assessed for each clinic using a multivariate Cox-proportional
hazards model. The model was adjusted for variation in the
following factors that have been shown to influence survival
outcomes: gender; age; HIV risk group (categorised as: Men who
have sex with men (MSM), heterosexual, injecting drug use or
other/unknown (including blood contact and vertical transmis-
sion)); region of origin (categorised as: Netherlands, Western
Europe and North America excluding the Netherlands, Sub
Saharan Africa, Latin America/ Caribbean and other); calendar
year of HIV diagnosis (categorised as: ,2000, 2000–2002, 2003–
2007); CD4 cell count at first presenting and, symptoms at first
presentation at the centre (categorised as: symptoms present or
not present). The risk of dying for each treatment centre was
compared to the risk of dying in the total population using hazard
ratios. The proportional hazard assumption was checked by
examining the distribution of the Schoenfeld residuals.
On this basis, three HIV treatment centres in the Netherlands
were selected for this study: centre A has approximately the same
risk of dying as the national average (Hazard ratio (HR): 0.85;
95% confidence interval: 0.54–1.31); centre B has the lowest
mortality rate (HR: 0.34; 0.12–0.98); and, centre C has the highest
mortality rate (HR: 3.28; 1.93–5.56). The risk of dying in the other
treatment centres varied between the risks of centres B and C.
To prevent differences in the socio-ethnicity status of patients
interfering with the comparison with the model, the mortality rates
in the three centres was then recalculated only for Dutch men that
acquired HIV through sex with men (i.e. Dutch MSM) (n=3946,
31% of the total dataset). Among these men, 21% initiated cART
before 1997 and 79% were initiated between 1997 and 2007.
For each of these three treatment centres, the following
distributions were found for the Dutch MSM entering care: (1)
the age-distribution (in five-year groups); (2) the average rate of
clinic visits for the patients being monitored for the need for cART
(i.e. those not yet on treatment); and, (3) the distribution of CD4
cell counts when first entering care. These data are used to
parameterise the mathematical model scenarios corresponding to
these centres.
Data: Natural History of HIV Infection among Dutch Men
Data from theATHENAnationalobservational cohort[13] were
used to estimate the common biological parameters describing
the natural history of HIV infection in this population. That is,
we assume that there are no differences in the clinical course of
infection between the men attending the different treatment centres
(this assumption is tested, see Results). The model (described in
more detail below) represents the course of infection by simulating
the decline in CD4 cell counts from an initial starting value
immediately after seroconversion.We used square-roottransformed
values of the CD4 cell counts. The distribution of the CD4 cell
count 6 monthsafterseroconversion forDutchMSMwasestimated
in a random effects model to have a mean value of 22.5, normally
distributed with standard deviation 0.45, for men aged less than 35;
and mean 21.2 and standard deviation 0.45 for men aged 35 years
and older. The rate of decline in CD4 cell count after the first
6 months of infection was assumed to be linear on the square-root
scale, which is in keeping with other analyses [14] [15] [16] and
theoretical [17] and clinical [18] observations. For men aged less
than 35 years, the rate of decline is 1.86 (Normally distributed with
standard deviation 0.17); for men aged 35 years or more, the rate is
2.10 (standard deviation 0.17).
Three-year survival rates on ART, stratified by CD4 cell count
when treatment is initiated, were estimated using ATHENA data,
pooled across all the treatment centres.
Mathematical model
A mathematical model representing patients entering care,
being monitored for the need to start treatment and treatment
outcomes was developed. The model has been described
previously [3] but the key features are described again here.
The model represents a cohort of individuals infected with
HIV at the same time. Each individual is assigned particular
characteristics (drawn randomly from the parametric distributions
estimated as described above), including their age at seroconver-
sion, the CD4 cell count after seroconversion, the rate of CD4
decline and the CD4 level at which they enter care in a treatment
centre.
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PLoS ONE | www.plosone.org 3 April 2008 | Volume 3 | Issue 4 | e1949Once in care, the need for cART is assessed. A CD4 cell count
is taken, but the measured value incorporates some measurement
error (uniformly distributed with mean zero) reflecting short-term
physiological variability and technical laboratory factors [19] [20].
If the CD4 cell count measurement is less than 250 cells per cubic
millimetre, then treatment is started. This threshold is based on the
median CD4 count at time cART initiation among Dutch MSM
in the Netherlands (median: 210 IQR: 100–320) and a sensitivity
analysis is conducted to check the influence of this assumption.
Whether or not that individual survives on cART for three-
years is determined probabilistically based on the estimated
chance of survival for individuals with that CD4 cell count. If
cART is not needed when the patient first enters care, the need for
cART is assessed again at another ‘appointment’ scheduled after a
set interval. After the CD4 cell count level reaches 50 and if
the patient has not started cART, is it assumed that survival is
exponentially distributed with mean 6 months.
The model scenarios representing the three treatment centres
were differentiated by the following three ‘treatment centre’
parameters: the age distribution of patients entering care, the
average rate of clinic visits of the patients not on cART and the
distribution of CD4 counts of patients first entering care. We
investigated: (1) whether the chance of individuals surviving on
cART varied between treatment centres when patients are
stratified by the initial CD4 cell count; (2) whether the model
could reproduce the observed variation in mortality between the
three treatment centres when parameterised in this way; and, (3)
the relative influence of these treatment centre parameters on the
predicted level of mortality on treatment.
Supporting Information
Figure S1 Sensitivity analysis. The analysis shown in Figure 2 in
the main text is repeated using alternative assumptions about the
CD4 cell count level at which treatment is initiated: (A) at 200 cell
per microlitre or less; (B) at 350 cells per microlitre or less. The
blue squares show the observed data; the red cross show the model
simulation with the parameters chosen to reflect conditions in each
treatment centre; the green circles show the model simulation
when the parameters are chosen to reflect conditions in each
treatment centre, with the exception that the distribution of CD4
cell count among patients entering care is the same in all centres.
Found at: doi:10.1371/journal.pone.0001949.s001 (0.03 MB TIF)
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